Alterity Therapeutics Ltd has released a press release.
First Patient dosed in ATH434 Phase 2 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity receives a $4.1 million R&D Tax Refund
- Regulatory Approval to Proceed with Phase 2 Trial in Italy
- Alterity Launches ATH434 Phase 2 Clinical Trial
- UK Regulatory Authorisation to Proceed with Phase 2 Trial
- New publication shows ATH434 rescues neurons in MSA model
Later from Alterity Therapeutics
- ATH434 Phase 2 clinical launched in Europe
- Appendix 4E & Annual Report 2022
- US FDA Approval for IND Application for ATH434 for MSA
- ATH434 Clinical Trial launched in Australia
- New US patent for compounds to treat neurodegeneration
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics